RESEARKA

Another tension arises between the neuroprotective and dementia-risk reduction signals of SGLT2 inhibitors and the absence of mechanistic clarity regarding how renal glucose excretion could protect the brain. This is a severity-5 disagreement within the contextual other outcome class. The mechanistic challenge is substantial: unlike cardiovascular benefits, which can be attributed to hemodynamic effects (preload reduction, afterload reduction, improved myocardial energetics via ketone body utilization), no established pathway connects renal glucose excretion to reduced amyloid deposition, tau phosphorylation, or neuroinflammation. Schonberger 2023 discusses immunomodulatory and anti-inflammatory effects of SGLT2 inhibitors, which could theoretically attenuate neuroinflammation, but this remains speculative without brain-specific biomarker data. The boundary condition for this tension is likely confounding by indication and healthy-user bias: patients prescribed SGLT2 inhibitors tend to have better metabolic profiles and more intensive overall diabetes management, which are themselves protective against cognitive decline. The evidence needed to resolve this tension includes Mendelian randomization studies using genetic instruments for SGLT2 activity and brain MRI biomarker endpoints in SGLT2 inhibitor trials, neither of which currently exist in the literature.

Citation Support

• source_1 Movila 2026
• source_2 Borges 2024
• source_3 Jansz 2026
• source_4 Ali 2026
• source_5 Cersosimo 2025